Inflammatory and circulatory effects of the reduction of endotoxin concentration in established porcine endotoxemic shock—A model of endotoxin elimination
暂无分享,去创建一个
A. Larsson | S. Rubertsson | M. Eriksson | J. Sjölin | E. Tano | M. Lipcsey | M. Carlsson
[1] A. Larsson,et al. EFFECT OF THE ADMINISTRATION RATE ON THE BIOLOGICAL RESPONSES TO A FIXED DOSE OF ENDOTOXIN IN THE ANESTHETIZED PIG , 2007, Shock.
[2] A. Larsson,et al. Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig , 2006, Journal of endotoxin research.
[3] D. Inthorn,et al. EXTRACORPOREAL PLASMA TREATMENT FOR THE REMOVAL OF ENDOTOXIN IN PATIENTS WITH SEPSIS: CLINICAL RESULTS OF A PILOT STUDY , 2005, Shock.
[4] J. Vincent,et al. A PILOT-CONTROLLED STUDY OF A POLYMYXIN B-IMMOBILIZED HEMOPERFUSION CARTRIDGE IN PATIENTS WITH SEVERE SEPSIS SECONDARY TO INTRA-ABDOMINAL INFECTION , 2005, Shock.
[5] R. Balogun,et al. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. , 2005, Critical care medicine.
[6] E. Neugebauer,et al. Extracorporeal endotoxin adsorption in septic patients--does it work? , 2004, Critical care medicine.
[7] J. Marshall,et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence , 2002, Critical care.
[8] Y. Kanno,et al. Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis , 2001, Blood Purification.
[9] E. Rietschel,et al. Bacterial lipopolysaccharides and innate immunity. , 2001, Journal of endotoxin research.
[10] S. Dower,et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. , 2001, The Journal of infectious diseases.
[11] J. A. Kruse,et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.
[12] S. Opal,et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. , 1999, The Journal of infectious diseases.
[13] T. van der Poll,et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.
[14] Craig R. Smith,et al. Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .
[15] T. Tani,et al. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. , 1994, American journal of surgery.
[16] J. Vincent,et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.
[17] Jerome J. Schentag,et al. A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .
[18] M. A. Martin,et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.
[19] J. Schellekens,et al. Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .
[20] J. Schellekens,et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. , 1990, The Journal of infectious diseases.
[21] P. Brandtzaeg,et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.
[22] J. McCutchan,et al. TREATMENT OF GRAM-NEGATIVE BACTEREMIA AND SHOCK WITH HUMAN ANTISERUM TO A MUTANT ESCHERICHIA COLI , 1983 .